Aclaris Therapeutics股价因2a期临床试验积极结果大涨

英为财情

2025/07/30

Investing.com -- Aclaris Therapeutics Inc (NASDAQ:ACRS)股价在宣布其ATI-2138治疗中度至重度特应性皮炎的2a期临床试验取得积极顶线结果后，盘后交易中飙升20%。这家临床阶段生物制药公司报告称，该试验达到了其目标，展示了良好的耐受性和临床上显著的疾病严重程度改善。研究涉及14名患者，他们接受了ATI-2138的低剂量治疗，这是一种...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555647460"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555647460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555647460?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-30 05:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555647460","market":"hk","top_or_hot":-1,"title":"Aclaris Therapeutics股价因2a期临床试验积极结果大涨","media":"英为财情","content":"<div>\n<p>Investing.com --  Aclaris Therapeutics Inc  (NASDAQ:ACRS)股价在宣布其ATI-2138治疗中度至重度特应性皮炎的2a期临床试验取得积极顶线结果后，盘后交易中飙升20%。\n这家临床阶段生物制药公司报告称，该试验达到了其目标，展示了良好的耐受性和临床上显著的疾病严重程度改善。研究涉及14名患者，他们接受了ATI-2138的低剂量治疗，这是一种...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2908600\">网页链接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclaris Therapeutics股价因2a期临床试验积极结果大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclaris Therapeutics股价因2a期临床试验积极结果大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-30 05:32 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/news/stock-market-news/article-93CH-2908600><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com --  Aclaris Therapeutics Inc  (NASDAQ:ACRS)股价在宣布其ATI-2138治疗中度至重度特应性皮炎的2a期临床试验取得积极顶线结果后，盘后交易中飙升20%。\n这家临床阶段生物制药公司报告称，该试验达到了其目标，展示了良好的耐受性和临床上显著的疾病严重程度改善。研究涉及14名患者，他们接受了ATI-2138的低剂量治疗，这是一种...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2908600\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2908600","article_id":"2555647460","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2908600","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555647460","pubTimestamp":1753824720,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com --  Aclaris Therapeutics Inc  股价在宣布其ATI-2138治疗中度至重度特应性皮炎的2a期临床试验取得积极顶线结果后，盘后交易中飙升20%。Aclaris首席执行官Neal Walker博士表示：\"这些2a期试验结果是我们ITK项目的重大成就，它证实了该机制并佐证了我们在下一代ITK选择性化合物上的工作。基于这些发现，Aclaris计划进一步开发ATI-2138用于斑秃治疗，同时探索与该药物作用机制相关的其他适应症。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1141":"生命科学工具和服务","BK1583":"高瓴概念","03347":"泰格医药","BK4007":"制药","BK1576":"医药外包概念","ACRS":"Aclaris Therapeutics","BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Aclaris Therapeutics stock jumps on positive results from phase 2a clinical trial","themeId":"fb31d1870ba8f7b9af5b9c771a889cfe","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRS":1,"LENZ":1,"03347":1},"content_text":"Investing.com --  Aclaris Therapeutics Inc  (NASDAQ:ACRS)股价在宣布其ATI-2138治疗中度至重度特应性皮炎的2a期临床试验取得积极顶线结果后，盘后交易中飙升20%。\n这家临床阶段生物制药公司报告称，该试验达到了其目标，展示了良好的耐受性和临床上显著的疾病严重程度改善。研究涉及14名患者，他们接受了ATI-2138的低剂量治疗，这是一种选择性口服抑制剂，靶向白细胞介素-2诱导性T细胞激酶(ITK)和Janus激酶3(JAK3)。\n结果显示，湿疹面积和严重程度指数(EASI)有所改善，并且按照峰值瘙痒数字评分量表测量，经历瘙痒严重程度减轻的患者百分比也有所增加。该公司强调，这些低剂量的疗效结果与已获批的JAK和IL-4/13抑制剂相当，但可能具有更好的耐受性。\nAclaris首席执行官Neal Walker博士表示：\"这些2a期试验结果是我们ITK项目的重大成就，它证实了该机制并佐证了我们在下一代ITK选择性化合物上的工作。\"\n药效学结果验证了ITK作为治疗靶点的价值，显示对关键炎症标志物的强烈下调。基于这些发现，Aclaris计划进一步开发ATI-2138用于斑秃治疗，同时探索与该药物作用机制相关的其他适应症。\n来自西奈山伊坎医学院的Emma Guttman博士指出，该试验的药效学结果令人信服，特别是观察到的抗炎活性以及ITK作为治疗靶点的潜力。\n\n本文由人工智能协助翻译。更多信息，请参见我们的使用条款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}